Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma

NCT06632951 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06632951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 20, 2025
Completion date
August 31, 2028
Enrollment
150 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma